New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing ...

The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

(HealthDay News) — Low testosterone levels may increase the risk of higher-grade “extreme” progression of prostate cancer among men enrolled in active surveillance (AS), according to a study published ...

Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while ...

Low testosterone may raise the risk of aggressive prostate cancer progression in men under monitoring, a study finds.

Based on the efficacy and safety data, Oric will advance the 400mg therapy to Phase III trials, with more treatment-emergent ...

Read more about how low testosterone levels are linked to ‘extreme’ disease progression in patients with prostate cancer ...

In late March 2026, ORIC Pharmaceuticals reported Phase 1b data showing that rinzimetostat 400 mg once daily plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

Prostate cancer is among the most prevalent cancers in men, particularly above the age of 50. In India, prostate cancer has been increasingly reported, with the urban population being at a higher risk ...